Evidence map›Paper›PMID 42210583›Full record

ArticleAdvanced healthcare materials2026

Self-Assembled Skin Equivalents with Monoclonal CRISPR/Cas9-Modified N/TERT-1 Keratinocytes: A Cutting-Edge Model for Human Skin and its Diseases.

Marta Slaufova, Tugay Karakaya, Michela Di Filippo, Thomas Kündig, Hans-Dietmar Beer

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marta SlaufovaDepartment of Dermatology, University Hospital Zurich, Schlieren, Switzerland.ORCID https://orcid.org/0000-0002-9860-7390
Tugay KarakayaDepartment of Dermatology, University Hospital Zurich, Schlieren, Switzerland.ORCID https://orcid.org/0000-0003-0683-579X
Michela Di FilippoDepartment of Dermatology, University Hospital Zurich, Schlieren, Switzerland.
Thomas KündigDepartment of Dermatology, University Hospital Zurich, Schlieren, Switzerland.
Hans-Dietmar BeerDepartment of Dermatology, University Hospital Zurich, Schlieren, Switzerland.ORCID https://orcid.org/0000-0002-8085-713X

Funding

Jubiläumsstiftung Swiss Life, Novartis Foundation for medical-biological Research #23C201LEO Foundation LF-OC-23-001156Monique Dornonville de la Cour FoundationSwiss National Science Foundation 310030_197426Vontobel Foundation 2360/2024Wolfermann-Nägeli Foundation 2025/09
6 · The paper itself

Abstract

Human skin is a complex organ consisting of multiple cell types and serves as an essential barrier against environmental stressors. Due to ethical considerations and interspecies differences, in vitro human skin equivalents (SEs) are increasingly used to complement or replace animal models in mechanistic, pharmacological, and disease-modeling studies. Scaffold-free full-thickness SEs, in which fibroblasts generate their own extracellular matrix, are particularly attractive because they provide high structural stability even during extended culture. However, the use of genetically defined keratinocyte populations in these SEs has remained limited. Here, scaffold-free full-thickness SEs incorporating wild-type, polyclonal or monoclonal CRISPR/Cas9-modified N/TERT-1 keratinocytes, generated via electroporation, are established. Monoclonal N/TERT-1 keratinocytes with targeted knockout (KO) of the crucial inflammasome component apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) form a differentiated epidermis but fail to secrete the proinflammatory cytokines interleukin (IL)-1β and IL-18 upon inflammasome activation, indicating complete functional ablation of inflammasome signaling in the 3D model. Moreover, SEs generated with gasdermin A (GSDMA)-KO N/TERT-1 keratinocytes illustrate the feasibility of analyzing genes induced during keratinocyte differentiation under physiological conditions. These results establish scaffold-free full-thickness SEs with monoclonal genetically modified N/TERT-1 keratinocytes as a robust and reproducible human skin model for mechanistic studies and future disease-modeling applications.

Indexed as

CRISPR-Cas SystemsKeratinocytesSkinSkin DiseasesCARD Signaling Adaptor ProteinsCell LineHumansInflammasomesInterleukin-1betaCARD Signaling Adaptor ProteinsInflammasomesInterleukin-1betacrispr/Cas9monoclonal knockoutN/TERT‐1 keratinocytesscaffold‐freeskin equivalent

Identifiers

PMID42210583
PMCPMC13331599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.